ヨーロッパの肺移植治療市場 – 業界動向と2029年までの予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

ヨーロッパの肺移植治療市場 – 業界動向と2029年までの予測

  • Pharmaceutical
  • Published Report
  • Feb 2022
  • Europe
  • 350 ページ
  • テーブル数: 209
  • 図の数: 43

>ヨーロッパの肺移植治療薬市場、製品別(免疫抑制剤、臓器保存製品、組織製品、その他)、適応症別(慢性閉塞性肺疾患(COPD)、肺線維症、敗血症性肺疾患、肺高血圧症、嚢胞性線維症、間質性肺線維症、肺気腫、サルコイドーシス、原発性肺動脈性高血圧症、その他)、タイプ別(死体肺移植、生体肺移植)、技術別(片肺移植、両肺移植、心肺移植、両肺移植)、患者層別(高齢者、成人、小児)、エンドユーザー別(病院、移植センター、専門センター、その他)、国別(ドイツ、スペイン、フランス、イタリア、英国、ベルギー、オランダ、スイス、ロシア、トルコ、その他のヨーロッパ)業界の動向と2029年までの予測

欧州の肺移植治療市場

市場分析と洞察:ヨーロッパの肺移植治療市場

ヨーロッパの肺移植治療市場は、2022年から2029年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に4.0%のCAGRで成長し、2029年までに6,415万米ドルに達すると分析しています。主要な市場プレーヤーによる新製品の発売は、予測期間中の市場の需要を促進すると予想されます。

肺移植は、病気の肺を切除し、別の人の健康な肺と交換する手術です。肺移植手術は、新生児から成人まで、65 歳まで、場合によってはそれ以降のほぼすべての年齢の人に行うことができます。肺移植は、他の薬や治療を試したが、基礎疾患が十分に改善しなかった、または時間の経過とともに悪化した人のためのものです。患者の病状に応じて、肺移植では片方の肺または両方の肺を交換する場合があります。状況によっては、ドナーの心臓とともに肺を移植することもあります。肺移植は、患者の健康と生活の質を大幅に改善することができます。

医薬品の承認数の増加、臨床試験の増加、慢性疾患の高発生率、治療への応用拡大に向けた進行中の研究が、市場の成長を牽引すると予想されます。ただし、臓器提供者の減少と肺移植手術のコストの高さが市場の成長を阻害する可能性があります。一方、医療費の増加、市場プレーヤーによる戦略的取り組み、肺移植の技術的進歩が市場の成長の機会を生み出す可能性があります。厳格な規制枠組みと肺移植に関連する合併症が市場の成長を阻む可能性があります。

ヨーロッパの肺移植治療市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析が提供されます。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームが、収益への影響ソリューションを作成し、希望する目標を達成できるようお手伝いします。

欧州の肺移植治療市場

欧州の肺移植治療市場の範囲と市場規模

ヨーロッパの肺移植治療市場は、製品、タイプ、適応症、技術、患者の人口統計、およびエンドユーザーに分類されています。セグメント間の成長は、ニッチな成長分野と市場へのアプローチ戦略を分析し、コアアプリケーション領域とターゲット市場の違いを判断するのに役立ちます。

  • 製品に基づいて、ヨーロッパの肺移植治療市場は、免疫抑制剤、組織製品、臓器保存製品、その他に分類されます。 2022年には、肺拒絶を回避するために患者が他の薬剤と組み合わせて免疫系抑制剤を消費することが増え、病院や小売店でこれらの薬剤が広く入手できるため、免疫抑制剤セグメントがヨーロッパの肺移植治療市場を支配すると予想されます。
  • タイプに基づいて、ヨーロッパの肺移植治療市場は、死体肺移植と生体肺移植に分類されます。2022年には、非政府組織やその他のいくつかの内部合弁企業による臓器提供とその応用に関する認識の高まりにより、死体肺移植セグメントがヨーロッパの肺移植治療市場を支配すると予想されます。
  • 適応症に基づいて、ヨーロッパの肺移植治療市場は、慢性閉塞性肺疾患(COPD)、肺線維症、敗血症性肺疾患、肺高血圧症、嚢胞性線維症、間質性肺線維症、肺気腫、原発性肺動脈性高血圧症サルコイドーシス、その他に分類されます。 2022年には、この地域の嚢胞性線維症患者の患者数の増加により、嚢胞性線維症セグメントが世界の肺移植治療市場を支配すると予想されます。
  • 技術に基づいて、ヨーロッパの肺移植治療市場は、片肺移植、両肺移植、心肺移植、両肺移植に分類されます。2022年には、ベルギー、スペイン、ドイツ、その他の地域での肺移植手術の急増により、片肺移植(SLT)セグメントがヨーロッパの肺移植治療市場を支配すると予想されます。
  • 患者の人口統計に基づいて、ヨーロッパの肺移植治療市場は、成人、小児、老年に分類されます。2022年には、成人人口に見られる健康上の合併症の増加と、肺移植の手順を決定する移植を待つ成人患者の待機リストの増加により、成人セグメントがヨーロッパの肺移植治療市場を支配すると予想されます。
  • エンドユーザーに基づいて、ヨーロッパの肺移植治療市場は、病院、移植センター、専門センター、その他に分類されます。病院は医療の主要な拠点であり、熟練した医師による手術に効果的な場所であり、臓器提供、登録、慢性疾患に関する意識が高まっているため、2022年には病院セグメントがヨーロッパの肺移植治療市場を支配すると予想されます。

ヨーロッパの肺移植治療市場の国別分析

ヨーロッパの肺移植治療市場が分析され、製品、タイプ、適応症、技術、患者の人口統計、およびエンドユーザーに基づいて市場規模の情報が提供されます。

ヨーロッパの肺移植治療市場に含まれる国としては、ドイツ、スペイン、フランス、イタリア、イギリス、ベルギー、オランダ、スイス、ロシア、トルコ、その他のヨーロッパ諸国などがあります。

ヨーロッパ地域の免疫抑制剤セグメントは、慢性疾患を予防するための臨床試験と研究開発の増加により、2022年から2029年の予測期間に最高の成長率で成長すると予想されています。ドイツは、肺移植手術が毎年増加し、移植用薬剤の承認が増えるため、ヨーロッパ市場の成長をリードすると予想されています。スペインは、研究開発への投資が継続的に増加し、医薬品の革新を促進することで優位に立つと予想されています。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。また、ヨーロッパ ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、販売チャネルの影響を考慮しながら、国別データの予測分析を提供します。

市場参加者による戦略的取り組みの評価

ヨーロッパの肺移植治療市場では、肺移植産業の各国の成長と売上、肺移植技術の進歩の影響、肺移植治療市場への支援に関する規制シナリオの変化など、詳細な市場分析も提供しています。データは、2011年から2020年までの履歴期間について入手できます。

競争環境と欧州の肺移植治療薬市場シェア分析

ヨーロッパの肺移植治療市場の競争状況は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と広さ、アプリケーションの優位性、技術ライフライン曲線などがあります。上記のデータ ポイントは、ヨーロッパの肺移植治療市場への会社の重点にのみ関連しています。

ヨーロッパの肺移植治療市場の主要メーカーとしては、Apotex Inc、Intas Pharmaceuticals Ltd.、Viatris Inc.、BioLife Solutions、Paragonix Technologies, Inc、Ose-immuno、XVIVO、Pfizer Inc.、F.Hoffmann-La Roche Ltd.、Panacea Biotec Ltd.、Astellas Pharma Inc.、Accord-UK Ltd、Novartis AG、Hikma Pharmaceuticals PLC、Dr. Franz Köhler Chemie GmbH、Detraxi Inc、Dr. Reddy's Laboratories Ltd.などが挙げられます。

さまざまな市場プレーヤーがより良いヘルスケア サービスを提供しており、ヨーロッパの肺移植治療市場も加速しています。

例えば、

  • 2022年1月、Hikma Pharmaceuticals PLCは、25種類の滅菌注射剤、3種類のライセンスを受けた眼科用製品、および7種類の追加製品のパイプライン(そのうち4種類はカナダ保健省の承認済み)を含むTeligent滅菌注射剤資産をカナダで拡大しました。この魅力的な製品ポートフォリオにより、同社は北米での事業を拡大し、この重要な市場で確固たる地位を築くことができます。

コラボレーション、製品の発売、事業拡大、受賞と表彰、合弁事業、その他の市場プレーヤーにより、ヨーロッパの肺移植治療市場における同社の地位が強化され、組織にとっても提供内容の改善に役立っています。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET END USERS COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 EPIDEMIOLOGY

4.2 PESTEL ANALYSIS

4.3 PORTER’S FIVE FORCES MODEL

5 INSURANCE AND REIMBURSEMENT - EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET

5.1 U.S.

5.2 EUROPE

5.3 CANADA

5.4 INDIA

6 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: REGULATIONS

6.1 REGULATION IN THE U.S.

6.2 REGULATION IN EUROPE

6.3 REGULATION IN NEW ZEALAND

6.4 REGULATION IN AUSTRALIA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASE IN INCIDENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

7.1.2 RISE IN AIR POLLUTION AND SURGE IN SMOKING

7.1.3 HIGH INCIDENCE OF CHRONIC DISEASES

7.1.4 RISE IN CLINICAL TRIALS

7.1.5 INCREASING DRUG APPROVALS

7.2 RESTRAINTS

7.2.1 LESS NUMBER OF DONORS FOR ORGAN DONATION

7.2.2 HIGH COST OF ORGAN TRANSPLANTATION

7.3 OPPORTUNITIES

7.3.1 RISING HEALTHCARE SPENDING

7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.3.3 TECHNOLOGICAL ADVANCEMENTS IN LUNG TRANSPLANTATION

7.4 CHALLENGES

7.4.1 STRINGENT REGULATORY FRAMEWORK

7.4.2 COMPLICATIONS ASSOCIATED WITH LUNG TRANSPLANTATION

8 IMPACT OF COVID-19 ON LUNG TRANSPLANT THERAPEUTICS MARKET

8.1 IMPACT ON PRICE

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC INITIATIVES

8.5 CONCLUSION

9 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT

9.1 OVERVIEW

9.2 IMMUNOSUPPRESSANT DRUGS

9.2.1 BY CLASS

9.2.1.1 CALCINEURIN INHIBITORS

9.2.1.1.1 TACROLIMUS

9.2.1.1.2 CYCLOSPORIN

9.2.1.2 ANTIMETABOLITE IMMUNOSUPPRESANTS

9.2.1.2.1 MYCOPHENOLATE MOFETIL

9.2.1.2.2 MYCOPHENOLATE SODIUM

9.2.1.2.3 AZATHIOPRINE

9.2.1.3 M-TOR INHIBITOR

9.2.1.3.1 SIROLIMUS

9.2.1.3.2 EVEROLIMUS

9.2.1.4 STEROIDS

9.2.1.4.1 METHYLPREDNISOLONE

9.2.1.4.2 PREDNISONE

9.2.1.5 MONOCLONAL ANTIBODY

9.2.1.5.1 BASILIXIMAB

9.2.1.5.2 MUROMONAB

9.2.1.6 OTHERS

9.2.2 BY DRUG TYPE

9.2.2.1 BRANDED

9.2.2.2 GENERIC

9.2.3 ROUTE OF ADMINISTRATION

9.2.3.1 ORAL ADMINISTRATION

9.2.3.2 PARENTERAL ADMINISTRATION

9.3 ORGAN PRESERVATION PRODUCTS

9.3.1 PERFADEX

9.3.2 HUMAN BIOSYSTEM (HBS) SOLUTION

9.3.3 LIFOR

9.3.4 CUSTODIOL HTK-(HISTIDINE-TRYPTOPHAN-KETOGLUTARATE) SOLUTION

9.3.5 RENOGRAF

9.3.6 OTHERS

9.4 TISSUE PRODUCT

9.5 OTHERS

10 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE

10.1 OVERVIEW

10.2 SINGLE-LUNG TRANSPLANT (SLT)

10.3 DOUBLE LUNG TRANSPLANT

10.4 BILATERAL LUNG TRANSPLANT (BLT)

10.5 HEART-LUNG TRANSPLANT

11 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS

11.1 OVERVIEW

11.2 ADULTS

11.3 GERIATRIC

11.4 PEDIATRIC

12 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE

12.1 OVERVIEW

12.2 CADAVERIC LUNG TRANSPLANT

12.3 LIVING LUNG TRANSPLANT

13 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION

13.1 OVERVIEW

13.2 CYSTIC FIBROSIS

13.3 PULMONARY FIBROSIS

13.4 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

13.5 INTERSTITIAL PULMONARY FIBROSIS

13.6 PULMONARY HYPERTENSION

13.7 PRIMARY PULMONARY ARTERIAL HYPERTENSION

13.8 EMPHYSEMA

13.9 SARCOIDOSIS

13.1 SEPTIC LUNG DISEASE

13.11 OTHERS

14 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITAL

14.3 TRANSPLANT CENTERS

14.4 SPECIALTY CENTERS

14.5 OTHERS

15 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION

15.1 EUROPE

15.1.1 GERMANY

15.1.2 SPAIN

15.1.3 FRANCE

15.1.4 ITALY

15.1.5 U.K.

15.1.6 BELGIUM

15.1.7 NETHERLANDS

15.1.8 SWITZERLAND

15.1.9 RUSSIA

15.1.10 TURKEY

15.1.11 REST OF EUROPE

16 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: EUROPE

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 ASTELLAS PHARMA INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENT

18.2 TRANSMEDICS (A SUBSIDIARY OF TRANSMEDICS GROUP, INC)

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENT

18.3 DR. REDDY’S LABORATORIES LTD.

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 F.HOFFMANN-LA ROCHE LTD.

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 HIKMA PHARMACEUTICALS PLC

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENT

18.6 APOTEX INC

18.6.1 COMPANY SNAPSHOT

18.6.2 PRODUCT PORTFOLIO

18.6.3 RECENT DEVELOPMENT

18.7 XVIVO

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENT

18.8 ACCORD-UK LTD

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 BIOLIFE SOLUTIONS

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENT

18.1 BRIDGE TO LIFE LTD

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 DETRAXI, INC.

18.11.1 COMPANY SNAPSHOT

18.11.2 PRODUCT PORTFOLIO

18.11.3 RECENT DEVELOPMENT

18.12 DR.FRANZ KOHLER CHEMIE GBMH

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENT

18.13 INTAS PHARMACEUTICALS LTD.

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENT

18.14 NOVARTIS AG

18.14.1 COMPANY SNAPSHOT

18.14.2 REVENUE ANALYSIS

18.14.3 PRODUCT PORTFOLIO

18.14.4 RECENT DEVELOPMENT

18.15 OSE-IMMUNO

18.15.1 COMPANY SNAPSHOT

18.15.2 PRODUCT PORTFOLIO

18.15.3 RECENT DEVELOPMENT

18.16 PANACEA BIOTEC LTD.

18.16.1 COMPANY SNAPSHOT

18.16.2 REVENUE ANALYSIS

18.16.3 PRODUCT PORTFOLIO

18.16.4 RECENT DEVELOPMENT

18.17 PARAGONIX TECHNOLOGIES, INC

18.17.1 COMPANY SNAPSHOT

18.17.2 PRODUCT PORTFOLIO

18.17.3 RECENT DEVELOPMENTS

18.17.3.1 PRODUCT LAUNCH

18.17.3.2 PARTNERSHIP

18.18 PFIZER INC.

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENT

18.19 VIATRIS, INC

18.19.1 COMPANY SNAPSHOT

18.19.2 REVENUE ANALYSIS

18.19.3 PRODUCT PORTFOLIO

18.19.4 RECENT DEVELOPMENT

18.20ST CENTURY MEDICINE

18.20.1 COMPANY SNAPSHOT

18.20.2 PRODUCT PORTFOLIO

18.20.3 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

表のリスト

TABLE 1 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 2 EUROPE IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 EUROPE IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 4 EUROPE CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 5 EUROPE ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 6 EUROPE M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 7 EUROPE STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 8 EUROPE MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 9 EUROPE IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 10 EUROPE IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 11 EUROPE ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 EUROPE ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 13 EUROPE TISSUE PRODUCT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 EUROPE OTHERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 16 EUROPE SINGLE-LUNG TRANSPLANT (SLT) IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 EUROPE DOUBLE LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 EUROPE BILATERAL LUNG TRANSPLANT (BLT) IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE HEART-LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 21 EUROPE ADULTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 EUROPE GERIATRIC IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 EUROPE PEDIATRIC IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 25 EUROPE CADAVERIC LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 EUROPE LIVING LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 28 EUROPE CYSTIC FIBROSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 EUROPE PULMONARY FIBROSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 EUROPE INTERSTITIAL PULMONARY FIBROSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 EUROPE PULMONARY HYPERTENSION IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 EUROPE PRIMARY PULMONARY ARTERIAL HYPERTENSION IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 EUROPE EMPHYSEMA IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 EUROPE SARCOIDOSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 EUROPE SEPTIC LUNG DISEASE IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 EUROPE OTHERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 39 EUROPE HOSPITAL IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 40 EUROPE TRANSPLANT CENTERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 EUROPE SPECIALTY CENTERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 42 EUROPE OTHERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 43 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 44 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 45 EUROPE IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 46 EUROPE CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 47 EUROPE ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 48 EUROPE M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 49 EUROPE STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 50 EUROPE MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 51 EUROPE IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 52 EUROPE IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 53 EUROPE ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 54 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 55 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 56 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 57 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 58 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 59 GERMANY LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 60 GERMANY IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 61 GERMANY CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 62 GERMANY ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 63 GERMANY M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 64 GERMANY STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 65 GERMANY MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 66 GERMANY IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 67 GERMANY IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 68 GERMANY ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 69 GERMANY LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 70 GERMANY LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 71 GERMANY LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 72 GERMANY LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 73 GERMANY LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 74 SPAIN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 75 SPAIN IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 76 SPAIN CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 77 SPAIN ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 78 SPAIN M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 79 SPAIN STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 80 SPAIN MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 81 SPAIN IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 82 SPAIN IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 83 SPAIN ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 84 SPAIN LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 85 SPAIN LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 86 SPAIN LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 87 SPAIN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 88 SPAIN LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 89 FRANCE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 90 FRANCE IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 91 FRANCE CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 92 FRANCE ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 93 FRANCE M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 94 FRANCE STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 95 FRANCE MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 96 FRANCE IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 97 FRANCE IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 98 FRANCE ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 99 FRANCE LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 100 FRANCE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 101 FRANCE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 102 FRANCE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 103 FRANCE LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 104 ITALY LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 105 ITALY IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 106 ITALY CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 107 ITALY ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 108 ITALY M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 109 ITALY STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 110 ITALY MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 111 ITALY IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 112 ITALY IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 113 ITALY ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 114 ITALY LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 115 ITALY LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 116 ITALY LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 117 ITALY LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 118 ITALY LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 119 U.K. LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 120 U.K. IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 121 U.K. CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 122 U.K. ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 123 U.K. M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 124 U.K. STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 125 U.K. MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 126 U.K. IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 127 U.K. IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 128 U.K. ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 129 U.K. LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 130 U.K. LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 131 U.K. LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 132 U.K. LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 133 U.K. LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 134 BELGIUM LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 135 BELGIUM IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 136 BELGIUM CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 137 BELGIUM ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 138 BELGIUM M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 139 BELGIUM STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 140 BELGIUM MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 141 BELGIUM IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 142 BELGIUM IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 143 BELGIUM ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 144 BELGIUM LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 145 BELGIUM LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 146 BELGIUM LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 147 BELGIUM LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 148 BELGIUM LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 149 NETHERLANDS LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 150 NETHERLANDS IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 151 NETHERLANDS CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 152 NETHERLANDS ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 153 NETHERLANDS M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 154 NETHERLANDS STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 155 NETHERLANDS MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 156 NETHERLANDS IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 157 NETHERLANDS IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 158 NETHERLANDS ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 159 NETHERLANDS LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 160 NETHERLANDS LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 161 NETHERLANDS LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 162 NETHERLANDS LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 163 NETHERLANDS LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 164 SWITZERLAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 165 SWITZERLAND IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 166 SWITZERLAND CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 167 SWITZERLAND ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 168 SWITZERLAND M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 169 SWITZERLAND STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 170 SWITZERLAND MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 171 SWITZERLAND IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 172 SWITZERLAND IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 173 SWITZERLAND ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 174 SWITZERLAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 175 SWITZERLAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 176 SWITZERLAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 177 SWITZERLAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 178 SWITZERLAND LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 179 RUSSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 180 RUSSIA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 181 RUSSIA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 182 RUSSIA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 183 RUSSIA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 184 RUSSIA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 185 RUSSIA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 186 RUSSIA IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 187 RUSSIA IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 188 RUSSIA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 189 RUSSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 190 RUSSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 191 RUSSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 192 RUSSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 193 RUSSIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 194 TURKEY LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 195 TURKEY IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 196 TURKEY CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 197 TURKEY ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 198 TURKEY M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 199 TURKEY STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 200 TURKEY MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 201 TURKEY IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 202 TURKEY IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 203 TURKEY ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 204 TURKEY LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)

TABLE 205 TURKEY LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 206 TURKEY LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 207 TURKEY LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

TABLE 208 TURKEY LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 209 REST OF EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

図表一覧

FIGURE 1 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: SEGMENTATION

FIGURE 2 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: MARKET END USERS COVERAGE GRID

FIGURE 8 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: SEGMENTATION

FIGURE 11 TECHNOLOGICAL ADVANCEMENTS IN HEALTHCARE AND SURGICAL SEGMENTS ASSOCIATED WITH ORGAN TRANSPLANTATION IS EXPECTED TO DRIVE THE EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 IMMUNOSUPPRESSANTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET

FIGURE 14 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, 2021

FIGURE 15 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, 2020-2029 (USD MILLION)

FIGURE 16 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, CAGR (2022-2029)

FIGURE 17 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 18 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, 2021

FIGURE 19 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, 2020-2029 (USD MILLION)

FIGURE 20 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, CAGR (2022-2029)

FIGURE 21 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, LIFELINE CURVE

FIGURE 22 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, 2021

FIGURE 23 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)

FIGURE 24 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, CAGR (2022-2029)

FIGURE 25 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, LIFELINE CURVE

FIGURE 26 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, 2021

FIGURE 27 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 28 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 29 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 30 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, 2021

FIGURE 31 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, 2020-2029 (USD MILLION)

FIGURE 32 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, CAGR (2022-2029)

FIGURE 33 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, LIFELINE CURVE

FIGURE 34 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, 2021

FIGURE 35 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, 2020-2029 (USD MILLION)

FIGURE 36 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, CAGR (2022-2029)

FIGURE 37 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, LIFELINE CURVE

FIGURE 38 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: SNAPSHOT (2021)

FIGURE 39 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2021)

FIGURE 40 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 41 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 42 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT (2022-2029)

FIGURE 43 EUROPE LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY SHARE 2021 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。